Medication Safety

MSATS – Safe use of medicines in palliative and end of life care

24 September 2025Discussion of medication safety challenges within palliative and end of life care; inspiring partnership across the system.

MSATS - Safe Use of DOACs

30 October 2024Discussion of key current medication safety challenges within healthcare with a focus on the safe use of DOACs; inspiring partnership across the system.

Learning from medication incidents and harms

15 December 2022Practical guidance to ensure opportunities to learn from local intelligence, including patient harm are translated into shared local and national learning

Investigating suspected tampering with medicines

11 June 2024A systematic approach should be taken to responding to reports of possible malicious tampering, securing the evidence, and seeking specialist advice and support

Including medicines with Risk Minimisation Measures (RMM) in PGDs

10 November 2025Medicines with RMM may not be suitable for inclusion within Patient Group Directions (PGDs). If used, the RMM must be stated within the PGD.

Improving the safe use of time critical medicines

18 December 2025A resource to support healthcare professionals in taking action to improve the safe use of time critical medicines.

Implementing self-administration of medicines

18 November 2024Individuals receiving healthcare should be supported to continue to self-administer existing/new medications unless there are reasons why they are unable to

Handling injectable cytotoxic medicines in clinical areas

17 November 2025Handling of injectable cytotoxic medicines in clinical areas should take into account risks to staff

Giving intermittent intravenous infusions by gravity in adults

6 September 2024Infusion by gravity is not the preferred method of administration, but may be necessary in some circumstances. Ensure a risk assessment is undertaken.

Ensuring time critical use of rasburicase

9 September 2025Timely use of rasburicase for treatment of tumour lysis syndrome is essential. Mitigation strategies can minimise harm associated with delayed therapy.